Evidence method
Level · gp.fundamentals.capex_revenue_ratio
4.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Jun 30, 2024
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-089342General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-40.06% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-11.72% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
30.59% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
55.27% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-109.56% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
58.70% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
30.00% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 3.61%
- Current
- 4.00%
- Delta
- 0.39%
- Previous
- -91.59%
- Current
- -40.06%
- Delta
- 51.53%
- Previous
- 11.23%
- Current
- -11.72%
- Delta
- -22.95%
- Previous
- 31.74%
- Current
- 30.59%
- Delta
- -1.15%
- Previous
- 56.89%
- Current
- 55.27%
- Delta
- -1.62%
- Previous
- -116.45%
- Current
- -109.56%
- Delta
- 6.89%
- Previous
- 72.23%
- Current
- 58.70%
- Delta
- -13.53%
- Previous
- 34.15%
- Current
- 30.00%
- Delta
- -4.14%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_INCREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →Transitioned To · ADPT GROWTH_DECREASED →Transitioned To · ADPT INVENTORY_PRESSURE_DECREASED →Transitioned To · ADPT MARGIN_DECREASED →Transitioned To · ADPT PROFITABILITY_INCREASED →Transitioned To · ADPT R_AND_D_INTENSITY_DECREASED →Transitioned To · ADPT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.